Skip to main navigation Skip to search Skip to main content

Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist

Research output: Contribution to journalArticlepeer-review

Abstract


Original languageEnglish
Article number2301008
JournalEuropean Respiratory Journal
Volume62
Issue number2
Early online date03 Aug 2023
DOIs
Publication statusEarly online date - 03 Aug 2023

Keywords

  • Sputum
  • Cystic Fibrosis - drug therapy
  • Humans
  • Inflammation

Cite this